Evidence map›Paper›PMID 34359774›Full record

ArticleCancers2021

Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer.

Maha Elazezy, Sandra Schwentesius, Luisa Stegat, Harriet Wikman, Stefan Werner, Wael Y Mansour, Antonio Virgilio Failla, Sven Peine, Volkmar Müller, Jean Paul Thiery and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Manipulating the EphB4-ephrinB2 axis to reduce metastasis in HNSCC.bioRxiv : the preprint server for biology · 2024
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Maha ElazezyDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Sandra SchwentesiusDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Luisa StegatDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Harriet WikmanDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0001-6862-0888
Stefan WernerDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Wael Y MansourDepartment of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0003-0641-2885
Antonio Virgilio FaillaUKE Microscopy Imaging Facility (UMIF), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Sven PeineDepartment of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Volkmar MüllerDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0003-4231-7906
Jean Paul ThieryBioland Laboratory, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510320, China.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, Sydney 2007, Australia.
Klaus PantelDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0001-5736-2772
Simon A JoosseDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0002-4296-5615
Universität Hamburg · DEGuangzhou Regenerative Medicine and Health Guangdong Laboratory · CNUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keratins are the main identification markers of circulating tumor cells (CTCs); however, whether their deregulation is associated with the metastatic process is largely unknown. Previously we have shown by in silico analysis that keratin 16 (

Indexed as

circulating tumor cells (CTCs)epithelial to mesenchymal transition (EMT)keratin 16 (KRT16)

Identifiers

PMID34359774
PMCPMC8345379
OpenAlexW3193230210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.